Louisiana-Pacific Corp. diskutieren
Louisiana-Pacific Corp.
WKN: 861032 / Symbol: LPX / Name: Louisiana-Pacifc / Aktie / Papier & Holz / Mid Cap /
85,08 €
-0,37 %
Louisiana-Pacific Co. (NYSE: LPX) was upgraded by analysts at TD Securities from a "hold" rating to a "buy" rating.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $82.00 price target on the stock, up previously from $49.00.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target lowered by analysts at Royal Bank of Canada from $90.00 to $85.00. They now have an "outperform" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target lowered by analysts at Truist Financial Co. from $82.00 to $79.00. They now have a "buy" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was upgraded by analysts at DA Davidson from a "neutral" rating to a "buy" rating. They now have a $76.00 price target on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was upgraded by analysts at TD Securities from a "hold" rating to a "buy" rating. They now have a $78.00 price target on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $78.00 price target on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target lowered by analysts at TD Securities from $75.00 to $71.00. They now have a "buy" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at Royal Bank of Canada from $72.00 to $80.00. They now have an "outperform" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at Truist Financial Co. from $75.00 to $82.00. They now have a "buy" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its "buy" rating re-affirmed by analysts at DA Davidson. They now have a $76.00 price target on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at Royal Bank of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at BMO Capital Markets from $83.00 to $99.00. They now have an "outperform" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at Royal Bank of Canada from $88.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at DA Davidson from $90.00 to $98.00. They now have a "buy" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) had its price target raised by analysts at DA Davidson from $98.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for LPX provided by MarketBeat
Louisiana-Pacific Co. (NYSE: LPX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $81.00 price target on the stock, down previously from $89.00.
Ratings data for LPX provided by MarketBeat
Neueste Beiträge
Deni43 in Arrowhead Pharmaceuticals Inc. diskutieren